{"id":7007,"date":"2024-07-17T12:25:00","date_gmt":"2024-07-17T12:25:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realheart-performs-a-directed-issue-of-units-to-underwriters-in-connection-with-the-completed-rights-issue-2\/"},"modified":"2024-07-17T12:25:00","modified_gmt":"2024-07-17T12:25:00","slug":"realheart-performs-a-directed-issue-of-units-to-underwriters-in-connection-with-the-completed-rights-issue-2","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realheart-performs-a-directed-issue-of-units-to-underwriters-in-connection-with-the-completed-rights-issue-2\/","title":{"rendered":"Realheart performs a directed issue of units to underwriters in connection with the completed rights issue"},"content":{"rendered":"
\n

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES.<\/strong><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB ("Realheart" or the "Company") announces that the Company's board, with the support of the authorization from the annual general meeting on June 7, 2024, has resolved to issue 6 300\u00a0000 units as underwriting compensation directed to a number of the underwriters who provided underwriting commitments in the rights issue that the Company carried out during the period June 12 to July 5, 2024, in accordance with the underwriting agreements entered into.<\/p>\n

The underwriters who provided underwriting commitments in the rights issue had the option of having the compensation paid out in cash or in the form of issued units in the Company, which was previously communicated in connection with the rights issue. In total, eight underwriters have chosen to have the underwriting compensation paid out in units. The Company's board has therefore resolved, with the support of the authorization from the annual general meeting on June 7, 2024, to issue 6 300 000 units as compensation to these underwriters, which will increase the company's number of shares by 12 600\u00a0000 shares and the company\u2019s share capital by 504\u00a0000.00 SEK. The purpose of the directed issue and the reason for the deviation from the shareholders\u2019 preferential rights is thus to fulfill the Company\u2019s commitments to the underwriters in accordance with the underwriting agreements.<\/p>\n

Units are issued at a price of 0.5 SEK per unit, corresponding to 0.25 SEK per share, which corresponds to the pricing of shares and units in the rights issue. The board's assessment is therefore that the subscription price is on market terms. The board has resolved that payment for units shall be made by offsetting the respective underwriter's claim on the Company. The underwriters\u2019 claim amounts to 3 150 000 SEK. When these 6\u00a0300\u00a0000 units together with the 48 610 406 units that were issued in the rights issue have been registered with the Swedish Companies Registration Office, the number of shares in the Company will amount to 206 815\u00a0258 shares, and the Company's share capital to approximately 8 272\u00a0610.32 SEK. The dilution that accrues as a result of the directed issue to the underwriters amounts to approximately 6.1 percent after the rights issue has been registered.<\/p>\n

Through the directed issue to the underwriters, 6 300 000 warrants of series TO3 are issued, which entitle the holder to subscribe for a maximum of 3 150 000 shares in the Company. Upon full exercise of the warrants, the share capital will increase by an additional maximum of SEK 126\u00a0000.00.<\/p>\n

The Company has had no specific costs related to the directed issue as this takes place as part of the work with the rights issue.<\/p>\n

Advisers<\/strong><\/p>\n

Skills Corporate Finance Nordic AB is financial adviser and Setterwalls Advokatbyr\u00e5 AB is legal adviser to Realheart in connection with the Rights Issue.<\/p>\n

Important information<\/p>\n

Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction.<\/p>\n

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade shares, warrants or other securities in Realheart. No action has been taken and no action will be taken to allow an offer to the public in any jurisdiction other than Sweden. The Swedish Financial Supervisory Authority's approval of the Prospectus shall not be construed as an approval of the Company's shares, warrants or other securities. However, this press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017\/1129 ("Prospectus Regulation"), and this press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Realheart. The information in this press release is only intended to describe the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance shall be given with respect to the accuracy or completeness of the information in this press release. Any investment decision should, in order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Rights Issue, be based solely on the information in the Prospectus. Therefore, an investor is recommended to read the entire Prospectus. This press release constitutes marketing in accordance with Article 2(k) of the Prospectus Regulation.<\/p>\n

The information in this press release may not be published, released or distributed, directly or indirectly, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require other actions than those following from Swedish law. Actions in violation of this instruction may constitute violations of applicable securities laws. No shares, warrants or other securities in Realheart have been registered, and no shares, warrants or other securities will be registered, under the then-applicable United States Securities Act of 1933 (the "Securities Act") or securities legislation in any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States except in accordance with an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or other jurisdiction in the United States.<\/p>\n

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, \u201cqualified investors\u201d who are (i) persons having professional experience in matters relating to investments who fall within the definition of \u201cinvestment professionals\u201d in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the \u201cOrder\u201d); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as \u201crelevant persons\u201d). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.<\/p>\n

For more information please contact:<\/p>\n

Ina Laura Perkins, CEO<\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/p>\n

E-mail: inalaura.perkins@realheart.se<\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB,\u00a0www.skmg.se<\/a><\/p>\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart\u00ae\u00a0TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation.\u00a0A unique concept in the medical technology world.<\/p>\n<\/div>\n

\n

For more information, please contact:<\/strong>
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21\u00a0
E-mail: inalaura.perkins@realheart.se<\/a>
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Scandinavian Real Heart is active in medical technology. The company conducts research and development in observations of the physiology of the heart. The development of the company's product, a complete artificial heart (TAH), takes place in collaboration with cardiac surgeons, researchers and engineers. The focus is on developing patented solutions that can imitate the blood circulation of the natural human heart. The solutions are intended for use by patients diagnosed with heart failure.<\/p>\n<\/div>\n

\n

Attachments<\/strong>
Realheart performs a directed issue of units to underwriters in connection with the completed rights issue<\/a><\/p>\n<\/div>\n